|**Name**|**Affiliation / Lab**|**Research Focus**| |---|---|---| |**[Jason T. Yustein, MD PhD](https://winshipcancer.emory.edu/bio/researcher/yustein-jason.html)**|[Emory University – Aflac Cancer & Blood Disorders Center](https://www.choa.org/research/aflac) / [Winship Cancer Institute](https://winshipcancer.emory.edu) (USA)|Pediatric sarcomas (Ewing, Osteosarcoma, Rhabdomyosarcoma); metastasis & therapy resistance; cross-species models & translational therapeutics| |**Tiruneh Adane Birlie**|Affiliation not confirmed (likely osteosarcoma program; possible Hudson Institute or ANZSA collaborator)|Single-cell transcriptomics + functional genomics for targeted combination therapies in osteosarcoma| |**[Jason Cain, PhD (A/Prof)](https://hudson.org.au/researcher-profile/associate-professor-jason-cain/)**|[Hudson Institute of Medical Research – Developmental & Cancer Biology / Sarcoma Program](https://hudson.org.au/research-theme/development-and-cancer-biology/)|AYA & pediatric sarcoma biology; multi-omics; therapy resistance; pre-clinical models| |**Charlotte Chen**|Affiliation not confirmed|Immunosuppressive tumor microenvironment in pediatric osteosarcoma| |**Mesalie Feleke**|[University of Western Australia](https://www.uwa.edu.au/)|Bone tumor microenvironment; single-cell studies in osteosarcoma and giant cell tumor of bone| |**[Angela Hong, MBBS PhD FRANZCR](https://www.mylifehouse.org.au/our-team/dr-angela-hong/)**|[Chris O’Brien Lifehouse](https://www.mylifehouse.org.au/) / [University of Sydney](https://www.sydney.edu.au/medicine-health/) / [GenesisCare](https://www.genesiscare.com/au/)|Radiation oncology; theranostics & imaging trials (⁸⁹Zr-olaratumab); sarcoma and melanoma| |**[Selvi Jegatheeson, BVSc (Hons) MANZCVS](https://www.petermac.org/research/labs)**|[Peter MacCallum Cancer Centre – Comparative Oncology Program](https://www.petermac.org/research/labs)|CAR-T therapy for osteosarcoma; canine-human comparative oncology; cancer immunology| |**Trisha Khoo, MBBS FRACP**|[Fiona Stanley Hospital](https://fsh.health.wa.gov.au/) (Perth)|Medical oncology; antibody–drug conjugates; desmoid tumor outcomes; NSAID/Tamoxifen therapy| |**Jason Qin**|Affiliation not confirmed|Real-world outcomes: cabozantinib in osteosarcoma / Ewing; sorafenib in desmoid tumors| |**[Kasia Chmiel, MBBS FRACP FAChPM](https://www.mylifehouse.org.au/our-team/dr-kasia-chmiel/)**|[Chris O’Brien Lifehouse – Palliative Care](https://www.mylifehouse.org.au/) (Sydney)|Integrative & AYA palliative care; end-of-life symptom management| |**James Ryan**|Affiliation not confirmed|Clear cell sarcoma and GNET case series; systemic therapy experience| |**[Vladimir Andelkovic, MD](https://iconcancercentre.com.au/doctor/vladimir-andelkovic/)**|[Icon Cancer Centre](https://iconcancercentre.com.au/) (Brisbane)|Medical oncology; sarcoma, breast & liver cancers; IDH1-mutant chondrosarcoma (Ivosidenib / CHONQUER study)|